{"id":"NCT02268214","sponsor":"AstraZeneca","briefTitle":"Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-11","primaryCompletion":"2017-01-04","completion":"2017-08-25","firstPosted":"2014-10-20","resultsPosted":"2018-03-29","lastUpdate":"2018-09-13"},"enrollment":833,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":[]},{"type":"DRUG","name":"Placebo for dapagliflozin","otherNames":[]}],"arms":[{"label":"Arm A: Dapagliflozin","type":"EXPERIMENTAL"},{"label":"Arm B: Dapagliflozin","type":"EXPERIMENTAL"},{"label":"Arm C: Placebo for Dapagliflozin","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.","primaryOutcome":{"measure":"Adjusted Mean Change in HbA1c From Baseline at Week 24","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Dapagliflozin 5 mg + Insulin","deltaMin":-0.45,"sd":0.0537},{"arm":"Dapagliflozin 10 mg + Insulin","deltaMin":-0.47,"sd":0.0538},{"arm":"Placebo + Insulin","deltaMin":-0.03,"sd":0.054}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":7},"locations":{"siteCount":131,"countries":["United States","Australia","Austria","Belgium","Canada","Denmark","Finland","France","Germany","Hungary","Israel","Italy","Mexico","Romania","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["39918875","38770818","35403243","32946821","32691513","30756462","30352894","28919061"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3676&filename=MB102229-revprot2_1_15.08.17_Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":37,"n":277},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Urinary tract infection","Influenza","Headache"]}}